NCT07675421Recruiting
Impact of HMB Supplementation on Inflammation and Outcomes in Head and Neck Cancer
Impact of Beta Hydroxy Methyl Butyrate (HMB) Supplementation on Inflammatory Markers and Clinical Outcomes in Patients With Head And Neck Cancer
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
Cancer patients undergoing surgery are at high risk of malnutrition due to the effects of the tumor and surgical stress, which can lead to worse clinical outcomes. This study aims to evaluate the impact of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammatory markers and clinical outcomes in patients with malignant tumors of the upper airways and digestive tract undergoing surgery. This is a randomized, double-blind clinical trial. Participants will be randomly assigned to one of two groups: intervention (3 g/day of HMB) or control (3 g/day of maltodextrin) for 30 days prior to surgery. Initial assessments will include nutritional status, muscle strength, quadriceps muscle thickness by ultrasound, and laboratory tests. Postoperative clinical outcomes will be monitored through electronic medical records.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 30 Sept 2025
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Federal University of Minas Gerais
- Diseases
- Head and neck cancer
- NCT number
- NCT07675421
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 1 Aug 2026 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid;
- Cognitive or intellectual impairment that may hinder proper understanding of the study;
Other
- Undergoing neoadjuvant or palliative treatment;
- Refusal to participate or to sign the informed consent form.
Who the study is looking for
- Individuals aged 18 years or older;
- Both sexes (male and female);
- Patients treated at the outpatient clinic for head and neck carcinoma;
- Indication for potentially curative tumor resection surgery.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| School of Medicine, Federal University of Minas Gerais Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.